Inhibition of platelet‐derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro
- 22 May 2007
- journal article
- Published by Wiley in Cell Proliferation
- Vol. 40 (3), 355-366
- https://doi.org/10.1111/j.1365-2184.2007.00438.x
Abstract
Recent data show that Imatinib mesylate (IM) also affects haematopoietic stem cells (HSC), T lymphocytes and dendritic cells that do not harbour constitutively active tyrosine kinases. We evaluated possible effects of IM on human bone marrow-derived mesenchymal stem cells (MSC) in vitro. Screening the activity of 42 receptor tyrosine kinases revealed an exclusive inhibition of platelet-derived growth factor receptorbeta (PDGFRbeta). Analysis of downstream targets of PDGFRbeta demonstrated IM-mediated reduction of Akt and Erk1/2 phosphorylation. Culture of MSC with IM led to the reversible development of perinuclear multi-vesicular bodies. The proliferation and clonogenicity of MSC were significantly reduced compared to control cultures. IM favoured adipogenic differentiation of MSC whereas osteogenesis was suppressed. The functional deficits described led to a 50% reduction in the support of clonogenic haematopoietic stem cells, cultured for 1 month on a monolayer of MSC with IM. In summary, inhibition of PDGFRbeta and downstream Akt and Erk signalling by IM has a significant impact on proliferation and differentiation of human MSC in vitro.Keywords
This publication has 31 references indexed in Scilit:
- Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre studyEuropean Journal of Haematology, 2005
- Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibBlood, 2005
- Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In VitroThe International Journal of Cell Cloning, 2004
- Inhibitory effect of imatinib on normal progenitor cells in vitroBlood, 2004
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2003
- Effects of imatinib on bone marrow engraftment in syngeneic miceLeukemia, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Pluripotency of mesenchymal stem cells derived from adult marrowNature, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaThe New England Journal of Medicine, 2002
- Mesenchymal stem cellsJournal of Orthopaedic Research, 1991